FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)  P&T Community Novartis anemia drug gets FDA priority review  MarketWatchFull coverage

from Health - Google News https://ift.tt/2J0Fqe4